Pamela Lewis
Family · Alabaster, ALNPI 1457021990
Payments from drug & device makers
Across 190 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$540
- AbbVie$459
- Lilly USA, LLC$338
- GSK$337
- AstraZeneca$250
- Exact Sciences$201
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,10799%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $540 |
| AbbVie | 40 | $459 |
| Lilly USA, LLC | 22 | $338 |
| GSK | 19 | $337 |
| AstraZeneca | 15 | $250 |
| Exact Sciences | 12 | $201 |
| Novo Nordisk | 9 | $175 |
| Bayer | 7 | $123 |
| Phathom Pharmaceuticals, Inc. | 6 | $106 |
| Dexcom, Inc. | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| Collegium Pharmaceutical, Inc. | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Atland Pharmaceuticals, LLC | 1 | $38 |
| Hologic Sales And Service, LLC | 2 | $34 |
| Shield Therapeutics Inc | 2 | $32 |
| Medline Industries LP | 1 | $30 |
| Amgen | 1 | $22 |
| Gilead | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Tris Pharma Inc | 1 | $21 |
| Biosense Webster, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$3,130 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $14,536 |
| Cefdinir | 27 | $463 |
| Azithromycin | 79 | $404 |
| Atorvastatin Calcium | 21 | $301 |
| Losartan Potassium | 22 | $297 |
| Pravastatin Sodium | 17 | $284 |
| Methylprednisolone | 23 | $221 |
| Levothyroxine Sodium | 25 | $216 |
| Lisinopril | 25 | $200 |
| Amlodipine Besylate | 18 | $186 |
| Fluticasone Propionate | 11 | $171 |
| Pantoprazole Sodium | 18 | $171 |
| Rosuvastatin Calcium | 15 | $168 |
| Cephalexin | 18 | $133 |
| Ciprofloxacin Hcl | 17 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $175 | $14,53614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.
Other family in Alabaster
- Christina RayAlabaster$16K
- Anne LoveAlabaster$13K
- Jaclyn FullerAlabaster$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.